Abstract:BACKGROUND:The immune status in the tumor micro-environment of lung cancer is highly informative, and expression status of some biomarkers in the tumor micro-environment may have deep connected statistical characteristics which could indicate immune status and predict related clinical outcomes. In this study, a panel of 9 immune biomarkers are selected for their possible predictive value of clinical outcomes in early-stage resectable non-small cell lung cancer (NSCLC).METHODS:We introduced a new way of interpreting the expression of Immunohistochemistry-based biomarkers in predicting the prognosis of patients. Immunohistochemistry were performed on surgical samples from 139 patients with NSCLC. Cox regression and subgroup analysis were conducted for the screening of biomarkers that were significant in survival and prognosis. Afterwards, Principle Component Analysis was conducted on screened biomarkers in order to extract characteristic root, which were utilized by an Artificial Neuron Network (ANN) for the prediction of clinical outcomes.RESULTS:Six out of 9 biomarkers were considered significant and were selected for the data analysis. The KMO-Bartlett's Sphericity test was valid (0.658>0.5, P=0.0001). The principle component regression results indicated that the survival was associated with the principle component Z4 (Y=0.316×Z4+2.298, R=0.189, P=0.026). Also, regression-free survival was associated with the principle component Z4 and Z2 (Y=0.314×Z4+0.255×Z2+2.061, R=0.249, P=0.013). Principle components ranking (PCrank) was calculated and after the determination of a cutoff of 0.2, the intergroup comparison of subgrouphigh (PCrank value above 0.2) and subgrouplow (PCrank value below 0.2) was significant in overall survival (OS) (P=0.025). A database search validated our results. Afterwards, the ANN model successfully predicted the clinical outcome, with accuracies of 94.1% and 96.2% respectively in models 1 and 2.CONCLUSIONS:The selected immunological panels have promising potential for predicting the prognosis of resectable NSCLC.

Immunohistochemistry In Undifferentiated Neoplasm/Tumor Of Uncertain Origin

Application of Immunohistochemistry in Undifferentiated Neoplasms: A Practical Approach.

Utility of immunohistochemistry in the pancreatobiliary tract.

Unknown Primary/Undifferentiated Neosplasms In Surgical And Cytologic Specimens

The application of immunohistochemical biomarkers in urologic surgical pathology.

Does Selected Immunological Panel Possess the Value of Predicting the Prognosis of Early-Stage Resectable Non-Small Cell Lung Cancer?

Comprehensive analysis of cancer of unknown primary and recommendation of a histological and immunohistochemical diagnostic strategy from China

Application of Immunohistochemistry in Thyroid Pathology

Application Of Immunohistochemistry In Gastrointestinal And Liver Neoplasms New Markers And Evolving Practice

Practical Immunohistochemistry In Neoplastic Pathology Of The Gastrointestinal Tract, Liver, Biliary Tract, And Pancreas

Immunohistochemistry in the diagnosis and classification of neuroendocrine neoplasms: what can brown do for you?

A Timely Update of Immunohistochemistry and Molecular Classification in the Diagnosis and Risk Assessment of Endometrial Carcinomas

Application of Immunohistochemistry to the Diagnosis of Primary and Metastatic Carcinoma to the Lung

Identification Of Immunohistochemical Markers For Distinguishing Lung Adenocarcinoma From Squamous Cell Carcinoma

Basic immunohistochemistry for lymphoma diagnosis

Precision in Diagnostic Molecular Pathology based on Immunohistochemistry.

Update on immunohistochemistry in bone and soft tissue tumors: Cost-effectively replacing molecular testing with immunohistochemistry

Immunocytochemical detection by a fully automated immunostainer for assisting subclassification of pulmonary tumors on ThinPrep slides in real-life clinical samples: A single-institution experience

Translation of gene expression profiles into a novel immunohistochemistry based classification of carcinoma

ROLE OF IMMUNOHISTOCHEMISTRY IN DIAGNOSIS AND AND SUBTYPING OF SOFT TISSUE TUMORS ACCORDING TO THE 2020 WHO CLASSIFICATION

Utility of Five Commonly Used Immunohistochemical Markers TTF-1, Napsin A, CK7, CK5/6 and P63 in Primary and Metastatic Adenocarcinoma and Squamous Cell Carcinoma of the Lung: a Retrospective Study of 246 Fine Needle Aspiration Cases.